Company intelligence / Profile preview

Enterprise Therapeutics

Brighton/Sussex area & London Blackfriars offices, England, United Kingdomenterprisetherapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

ETD001, the company's lead compound targeting ENaC for cystic fibrosis and other respiratory diseases, entered Phase 2 trials in early 2024. The program has also received rare pediatric disease designation from the FDA in September 2024. The approach aims to be mutation agnostic and disease-modifying by improving airway hydration and mucus clearance. No published late-stage results yet.

Therapeutic areas: Pulmonology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

ETD001

2 more assets in the full pipeline.

Request access →

Partnerships

Backed by top-tier venture capital investors including Novartis Venture Fund, Versant Ventures, Forbion, IP Group Life Sciences Investment Team, Panakes Partners.

Beyond the preview

Go deeper on Enterprise Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enterprise Therapeutics.

Explore the full profile